New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
07:38 EDTPPHMPeregrine receives FDA fast track designation for Bavituximab
Peregrine Pharmaceuticals announced that the company has received Fast Track designation by the FDA for its lead investigational immunotherapy bavituximab for the potential treatment of second-line non-small cell lung cancer, or NSCLC. Recently, the company initiated SUNRISE, a pivotal Phase III clinical trial comparing bavituximab plus the chemotherapy docetaxel against placebo plus docetaxel in this indication.
News For PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
08:40 EDTPPHMPeregrine granted keu EU patent for bavituximab
Peregrine Pharmaceuticals announced that the European Patent Office, or EPO, has granted Patent Number 2,269,656, titled "Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer”. This important patent covers bavituximab as a composition of matter and for use in treating cancer including in combination with radiotherapy or chemotherapy, such as with docetaxel. The new patent covers bavituximab as a composition of matter, a range of related antibodies, including humanized and chain-shuffled antibodies and other sequence variations and their broad use in any diagnosis or therapy. The new patent also covers antibody drug conjugates, diagnostic and imaging constructs, liposomal and pharmaceutical combinations of bavituximab and related antibodies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use